The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Heinz-Josef Klümpen
No Relationships to Disclose
 
Gianluca Masi
Consulting or Advisory Role - AstraZeneca; Eisai; MSD Oncology
Patents, Royalties, Other Intellectual Property - Terumo (Inst)
 
Alessandro Granito
No Relationships to Disclose
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Masatoshi Kudo
Honoraria - Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Research Funding - Abbvie (Inst); Chugai/Roche; EA Pharma (Inst); Eisai (Inst); GE Healthcare; Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Shukui Qin
No Relationships to Disclose
 
René Gerolami
No Relationships to Disclose
 
Yi-Hsiang Huang
No Relationships to Disclose
 
Do Young Kim
No Relationships to Disclose
 
Matthias Pinter
Honoraria - AstraZeneca; Bayer; BMS GmbH & Co. KG; Eisai; Ipsen; Lilly; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; BMS GmbH & Co. KG; Eisai; Ipsen; Lilly; MSD; Roche
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Roche
 
Naoya Kato
Speakers' Bureau - Abbott; Abbvie; Aska Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb Company; Chugai Pharma; Covidien; Daiichi Sankyo Co.,Ltd.; EA Pharma; Eisai; Fujifilm; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Mylan; Nichi-iko; Nippon Kayaku; Nobelpharma; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Takeda; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Aska Pharmaceutical Co.,Ltd. (Inst); Astellas Pharma (Inst); Boston Scientific (Inst); Chugai Pharma (Inst); Covidien (Inst); CYTLIMIC (Inst); Daiichi Sankyo co.,Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); JIMRO (Inst); Kowa (Inst); Medicos Hirata (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Shionogi (Inst); Sumitomo Dainippon Pharma Co.,Ltd. (Inst); Takeda (Inst); Tsumura & Co. (Inst)
 
Masayuki Kurosaki
Speakers' Bureau - Abbvie; Chugai Pharma; Eisai; Gilead Sciences; Janssen; Lilly Japan; Takeda
 
Kazushi Numata
No Relationships to Disclose
 
Javeed Khan
Employment - Bayer
 
Kirhan Ozgurdal
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Yoon Jun Kim
Research Funding - Bristol-Myers Squibb; Bukwang Pharmaceutical; Handok; Hanmi; JW Creagene; PharmaKing; Roche; Yuhan
Other Relationship - Bayer; Bukwang Pharmaceutical; CJ Pharmaceutical; Gilead Sciences; Handok; MSD; Samil Pharmaceutical; Yuhan